CA2241205A1 - Pharmaceutical compositions with vitamin d analogues - Google Patents
Pharmaceutical compositions with vitamin d analogues Download PDFInfo
- Publication number
- CA2241205A1 CA2241205A1 CA002241205A CA2241205A CA2241205A1 CA 2241205 A1 CA2241205 A1 CA 2241205A1 CA 002241205 A CA002241205 A CA 002241205A CA 2241205 A CA2241205 A CA 2241205A CA 2241205 A1 CA2241205 A1 CA 2241205A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- vitamin
- hydrogen atom
- cyclodextrin
- pharmaceutical preparations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19549243.9 | 1995-12-21 | ||
| DE19549243A DE19549243A1 (de) | 1995-12-21 | 1995-12-21 | Pharmazeutische Präparate enthaltend Clathrate von Cyclodextrinen und nichtnatürliche Vitamin D-Analoga |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2241205A1 true CA2241205A1 (en) | 1997-07-03 |
Family
ID=7781710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002241205A Abandoned CA2241205A1 (en) | 1995-12-21 | 1996-12-20 | Pharmaceutical compositions with vitamin d analogues |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0869819A1 (hu) |
| JP (1) | JP2000502733A (hu) |
| KR (1) | KR19990076637A (hu) |
| CN (1) | CN1207687A (hu) |
| AU (1) | AU1306997A (hu) |
| CA (1) | CA2241205A1 (hu) |
| DE (1) | DE19549243A1 (hu) |
| HU (1) | HUP9903935A3 (hu) |
| IL (1) | IL125020A0 (hu) |
| IS (1) | IS4774A (hu) |
| NO (1) | NO982874L (hu) |
| WO (1) | WO1997023242A1 (hu) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100048511A1 (en) * | 2006-11-06 | 2010-02-25 | Hanmi Pharm Co., Ltd. | Complex formulation for preventing or treating osteoporosis which comprises solid dispersion of vitamin d or its derivative and bisphosphonate |
| US8207149B2 (en) | 2007-04-25 | 2012-06-26 | Cytochroma, Inc. | Method for treating secondary hyperparathyroidism in CKD |
| US8329677B2 (en) | 2006-06-21 | 2012-12-11 | Cytochroma, Inc. | Method of treating and preventing secondary hyperparathyroidism |
| US8426391B2 (en) | 2006-02-03 | 2013-04-23 | Proventiv Therapeutics, Llc | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
| US8592401B2 (en) | 2007-04-25 | 2013-11-26 | Proventiv Therapeutics, Llc | Methods and compounds for vitamin D therapy |
| US9861644B2 (en) | 2013-03-15 | 2018-01-09 | Opko Ireland Global Holdings, Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| US10302660B2 (en) | 2008-04-02 | 2019-05-28 | Opko Renal, Llc | Methods useful for vitamin D deficiency and related disorders |
| US11173168B2 (en) | 2016-03-28 | 2021-11-16 | Eirgen Pharma Ltd. | Methods of treating vitamin D insufficiency in chronic kidney disease |
| US11672809B2 (en) | 2010-03-29 | 2023-06-13 | Eirgen Pharma Ltd. | Methods and compositions for reducing parathyroid levels |
| US11752158B2 (en) | 2007-04-25 | 2023-09-12 | Eirgen Pharma Ltd. | Method of treating vitamin D insufficiency and deficiency |
| US11801253B2 (en) | 2007-04-25 | 2023-10-31 | Opko Renal, Llc | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6538037B2 (en) | 1991-01-08 | 2003-03-25 | Bone Care International, Inc. | Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2 |
| US6566353B2 (en) | 1996-12-30 | 2003-05-20 | Bone Care International, Inc. | Method of treating malignancy associated hypercalcemia using active vitamin D analogues |
| US6573256B2 (en) | 1996-12-30 | 2003-06-03 | Bone Care International, Inc. | Method of inhibiting angiogenesis using active vitamin D analogues |
| US6503893B2 (en) | 1996-12-30 | 2003-01-07 | Bone Care International, Inc. | Method of treating hyperproliferative diseases using active vitamin D analogues |
| GB9826656D0 (en) | 1998-12-03 | 1999-01-27 | Novartis Ag | Organic compounds |
| DE102005017775A1 (de) * | 2005-04-13 | 2006-10-19 | Schering Ag | Komplexe aus Vitamin D-Verbindungen oder deren Analoga mit einem 5Z,7E,10(19)-Trien-System und methlierten Derivaten des ß-Cyclodextrins |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU177586B (en) * | 1978-12-19 | 1981-11-28 | Chinoin Gyogyszer Es Vegyeszet | New process for preparing stable inclusion complexes of vitamine d with cyclodextrin |
| JPS5910562A (ja) * | 1982-07-07 | 1984-01-20 | Teijin Ltd | プレ−１α−ヒドロキシコレカルシフエロ−ル類の製造法 |
| JPS5936656A (ja) * | 1982-08-23 | 1984-02-28 | Teijin Ltd | 新規包接化合物及びそれを活性成分とする薬剤 |
| JPS60120812A (ja) * | 1983-12-02 | 1985-06-28 | Teijin Ltd | 糖尿病性骨減少症治療剤 |
| EP0437225B1 (de) * | 1990-01-10 | 1994-04-20 | F. Hoffmann-La Roche Ag | Topische Präparate |
| IL107185A (en) * | 1992-10-06 | 1998-02-22 | Schering Ag | History of 52-carboxylic acid, processes for their preparation and pharmaceutical preparations containing them |
-
1995
- 1995-12-21 DE DE19549243A patent/DE19549243A1/de not_active Withdrawn
-
1996
- 1996-12-20 HU HU9903935A patent/HUP9903935A3/hu unknown
- 1996-12-20 KR KR1019980704745A patent/KR19990076637A/ko not_active Application Discontinuation
- 1996-12-20 WO PCT/EP1996/005856 patent/WO1997023242A1/de not_active Application Discontinuation
- 1996-12-20 JP JP9523335A patent/JP2000502733A/ja active Pending
- 1996-12-20 CA CA002241205A patent/CA2241205A1/en not_active Abandoned
- 1996-12-20 AU AU13069/97A patent/AU1306997A/en not_active Abandoned
- 1996-12-20 IL IL12502096A patent/IL125020A0/xx unknown
- 1996-12-20 CN CN96199734A patent/CN1207687A/zh active Pending
- 1996-12-20 EP EP96944669A patent/EP0869819A1/de not_active Withdrawn
-
1998
- 1998-06-15 IS IS4774A patent/IS4774A/is unknown
- 1998-06-19 NO NO982874A patent/NO982874L/no not_active Application Discontinuation
Cited By (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11007204B2 (en) | 2006-02-03 | 2021-05-18 | Opko Renal, Llc | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
| US10213442B2 (en) | 2006-02-03 | 2019-02-26 | Opko Renal, Llc | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
| US8906410B2 (en) | 2006-02-03 | 2014-12-09 | Opko Health, Inc. | Oral dosage form of 25-hydroxyvitamin D |
| US11911398B2 (en) | 2006-02-03 | 2024-02-27 | Opko Renal, Llc | Treating Vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
| US8426391B2 (en) | 2006-02-03 | 2013-04-23 | Proventiv Therapeutics, Llc | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
| US9943530B2 (en) | 2006-02-03 | 2018-04-17 | Opko Renal, Llc | Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
| US9913852B2 (en) | 2006-06-21 | 2018-03-13 | Opko Ireland Global Hodlings, Ltd. | Method of treating and preventing secondary hyperparathyroidism |
| US8329677B2 (en) | 2006-06-21 | 2012-12-11 | Cytochroma, Inc. | Method of treating and preventing secondary hyperparathyroidism |
| US10668089B2 (en) | 2006-06-21 | 2020-06-02 | Opko Ireland Global Holdings, Ltd. | Method of treating and preventing secondary hyperparathyroidism |
| US9402855B2 (en) | 2006-06-21 | 2016-08-02 | Opko Renal, Llc | Method of treating and preventing secondary hyperparathyroidism |
| US20100048511A1 (en) * | 2006-11-06 | 2010-02-25 | Hanmi Pharm Co., Ltd. | Complex formulation for preventing or treating osteoporosis which comprises solid dispersion of vitamin d or its derivative and bisphosphonate |
| US8778373B2 (en) | 2007-04-25 | 2014-07-15 | Opko IP Holdings II, Inc. | Methods for controlled release oral dosage of a vitamin D compound |
| US11801253B2 (en) | 2007-04-25 | 2023-10-31 | Opko Renal, Llc | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
| US9918940B2 (en) | 2007-04-25 | 2018-03-20 | Opko Renal, Llc | Methods for controlled release oral dosage of a vitamin D compound |
| US9925147B2 (en) | 2007-04-25 | 2018-03-27 | Opko Renal, Llc | Method for treating secondary hyperparathyroidism in CKD |
| US9498486B1 (en) | 2007-04-25 | 2016-11-22 | Opko Renal, Llc | Method for controlled release oral dosage of a vitamin D compound |
| US8207149B2 (en) | 2007-04-25 | 2012-06-26 | Cytochroma, Inc. | Method for treating secondary hyperparathyroidism in CKD |
| US8592401B2 (en) | 2007-04-25 | 2013-11-26 | Proventiv Therapeutics, Llc | Methods and compounds for vitamin D therapy |
| US9408858B2 (en) | 2007-04-25 | 2016-08-09 | Opko Renal, Llc | Method for treating secondary hyperparathyroidism in CKD |
| US11752158B2 (en) | 2007-04-25 | 2023-09-12 | Eirgen Pharma Ltd. | Method of treating vitamin D insufficiency and deficiency |
| US11154509B2 (en) | 2007-04-25 | 2021-10-26 | Eirgen Pharma Ltd. | Methods for controlled release oral dosage of a vitamin D compound |
| US8361488B2 (en) | 2007-04-25 | 2013-01-29 | Cytochroma Inc. | Methods and compositions for controlled release oral dosage of a vitamin D compound |
| US10302660B2 (en) | 2008-04-02 | 2019-05-28 | Opko Renal, Llc | Methods useful for vitamin D deficiency and related disorders |
| US11672809B2 (en) | 2010-03-29 | 2023-06-13 | Eirgen Pharma Ltd. | Methods and compositions for reducing parathyroid levels |
| US10357502B2 (en) | 2013-03-15 | 2019-07-23 | Opko Ireland Global Holdings, Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
| US10350224B2 (en) | 2013-03-15 | 2019-07-16 | Opko Ireland Global Holdings, Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
| US11253528B2 (en) | 2013-03-15 | 2022-02-22 | Eirgen Pharma Ltd. | Stabilized modified release Vitamin D formulation and method of administering same |
| US10300078B2 (en) | 2013-03-15 | 2019-05-28 | Opko Ireland Global Holdings, Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
| US9861644B2 (en) | 2013-03-15 | 2018-01-09 | Opko Ireland Global Holdings, Ltd. | Stabilized modified release vitamin D formulation and method of administering same |
| US10493084B2 (en) | 2014-08-07 | 2019-12-03 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| US11007205B2 (en) | 2014-08-07 | 2021-05-18 | Eirgen Pharma Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| US11738033B2 (en) | 2014-08-07 | 2023-08-29 | Eirgen Pharma Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| US11173168B2 (en) | 2016-03-28 | 2021-11-16 | Eirgen Pharma Ltd. | Methods of treating vitamin D insufficiency in chronic kidney disease |
Also Published As
| Publication number | Publication date |
|---|---|
| DE19549243A1 (de) | 1997-06-26 |
| AU1306997A (en) | 1997-07-17 |
| KR19990076637A (ko) | 1999-10-15 |
| CN1207687A (zh) | 1999-02-10 |
| HUP9903935A3 (en) | 2000-05-29 |
| IL125020A0 (en) | 1999-01-26 |
| NO982874L (no) | 1998-08-20 |
| NO982874D0 (no) | 1998-06-19 |
| IS4774A (is) | 1998-06-15 |
| WO1997023242A1 (de) | 1997-07-03 |
| HUP9903935A2 (hu) | 2000-03-28 |
| EP0869819A1 (de) | 1998-10-14 |
| JP2000502733A (ja) | 2000-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2241205A1 (en) | Pharmaceutical compositions with vitamin d analogues | |
| CA1228812A (en) | Process for the manufacture of novel topically administrable pharmaceutical compositions | |
| US5385943A (en) | Use of topically applicable preparations for treatment of presbyderma | |
| CA2141704C (fr) | Solutions aqueuses concentrees d'argatroban | |
| EP0585170B1 (fr) | Composition pour le traitement de l'acné contenant au moins un dérivé d'acide salicylique | |
| CA2406570C (en) | Dermal compositions containing coenzyme q as the active ingredient | |
| JP5873439B2 (ja) | ビタミンｄ類似体および溶媒と界面活性剤の混合物を含む皮膚組成物 | |
| EP0973524B1 (fr) | Utilisation cosmetique ou dermatologique de steroides 7-hydroxyles | |
| JP5548275B2 (ja) | ビタミンｄ類似体および共溶媒−界面活性剤混合物から成る医薬品組成物 | |
| JPH11506791A (ja) | ガンを治療するためのビタミンｄ４誘導体の使用 | |
| US20140322331A1 (en) | Calcipotriol monohydrate nanocrystals | |
| EP0788361A1 (fr) | Nouvelles compositions a base d'un melange synergetique entre au moins un ligand de vdr et un retinoide | |
| EP2515866A2 (en) | Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue | |
| US5362719A (en) | Use of vitamin-D analogues in the treatment of acne | |
| EP2251004A2 (fr) | Composition pharmaceutique ou cosmétique, et procédé de solubilisation mixte pour préparer la composition | |
| EP0223671B1 (fr) | Médicament à action synergétique anti-inflammatoire à base d'un corticostéroide et d'un beta-agoniste | |
| JP2006249010A (ja) | 皮膚外用剤 | |
| JP4361789B2 (ja) | 体表の過剰増殖疾患の処置 | |
| EP0639377A1 (en) | Vitamin D compounds with anti-progesterone activity | |
| JP2889864B2 (ja) | 結晶態のビタミンｄ誘導体 | |
| JPS6226223A (ja) | 乾癬治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |